LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 248

Search options

  1. Article ; Online: Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down.

    Campochiaro, Corrado / Matucci-Cerinic, Marco

    Rheumatology (Oxford, England)

    2023  Volume 63, Issue 3, Page(s) 589–590

    MeSH term(s) Humans ; Lung Diseases, Interstitial/etiology ; Lung ; Scleroderma, Systemic/complications
    Language English
    Publishing date 2023-09-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kead504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: PET in Takayasu arteritis: onwards and upwards towards a future of robust multimodality disease activity assessment?

    Campochiaro, Corrado / Misra, Durga Prasanna

    Rheumatology (Oxford, England)

    2021  Volume 61, Issue SI, Page(s) SI4–SI5

    MeSH term(s) Humans ; Multimodal Imaging ; Positron-Emission Tomography ; Takayasu Arteritis/diagnostic imaging
    Language English
    Publishing date 2021-08-09
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab644
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.

    Campochiaro, Corrado / Allanore, Yannick

    Arthritis research & therapy

    2021  Volume 23, Issue 1, Page(s) 155

    Abstract: New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of ... ...

    Abstract New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of the first drug licenced for SSc-related interstitial lung disease. Given this exciting time in the SSc field, we aimed to perform a systemic literature review of phase 1, phase 2 and phase 3 clinical trials and large observational studies about targeted therapies in SSc. We searched MEDLINE/PubMed, EMBASE, and ClinicalTrials.gov for clinical studies from 2016 with targeted therapies as the primary treatment in patients with SSc for skin or lung involvement as the primary clinical outcome measure. Details on the study characteristics, the trial drug used, the molecular target engaged by the trial drug, the inclusion criteria of the study, the treatment dose, the possibility of concomitant immunosuppression, the endpoints of the study, the duration of the study and the results obtained were reviewed. Of the 973 references identified, 21 (4 conference abstracts and 17 articles) were included in the systematic review. A total of 15 phase 1/phase 2 clinical trials, 2 phase 3 clinical trials and 2 observation studies were analysed. The drugs studied in phase 1/phase 2 studies included the following: inebilizumab, dabigatran, C-82, pomalidomide, rilonacept, romilkimab, tocilizumab, tofacitinib, pirfenidone, lenabasum, abatacept, belimumab, riociguat, SAR100842 and lanifibranor. All but 3 studies were performed in early diffuse SSc patients with different inclusion criteria, while 3 studies were performed in SSc patients with interstitial lung disease (ILD). Phase 3 clinical trials investigated nintedanib and tocilizumab. Nintedanib was investigated in SSc-ILD patients whereas tocilizumab focused on early diffuse SSc patients with inflammatory features. Two observational studies including > 50 patients with rituximab as the targeted drug were also evaluated. All these studies offer a real hope for SSc patients. The future challenges will be to customize patient-specific therapeutics with the goal to develop precision medicine for SSc.
    MeSH term(s) Humans ; Lung Diseases, Interstitial ; Scleroderma, Diffuse ; Scleroderma, Systemic
    Language English
    Publishing date 2021-06-01
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 2107602-9
    ISSN 1478-6362 ; 1478-6354
    ISSN (online) 1478-6362
    ISSN 1478-6354
    DOI 10.1186/s13075-021-02536-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Allopurinol-induced severe cutaneous adverse reactions.

    Campochiaro, Corrado

    Annals of the rheumatic diseases

    2016  Volume 75, Issue 4, Page(s) e20

    MeSH term(s) Allopurinol/adverse effects ; Antigens, Differentiation, T-Lymphocyte/blood ; Drug Eruptions/etiology ; Female ; HLA-B Antigens/immunology ; Humans ; Male ; Oxypurinol/blood ; Renal Insufficiency/etiology
    Chemical Substances Antigens, Differentiation, T-Lymphocyte ; HLA-B Antigens ; Allopurinol (63CZ7GJN5I) ; Oxypurinol (G97OZE5068)
    Language English
    Publishing date 2016-04
    Publishing country England
    Document type Comment ; Letter
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2015-209108
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The conundrum of interleukin-6 blockade in COVID-19.

    Campochiaro, Corrado / Dagna, Lorenzo

    The Lancet. Rheumatology

    2020  Volume 2, Issue 10, Page(s) e579–e580

    Keywords covid19
    Language English
    Publishing date 2020-08-14
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30287-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Lights and shadows on JAK inhibitors for Ankylosing Spondylitis.

    Benanti, Giovanni / Dagna, Lorenzo / Campochiaro, Corrado

    European journal of internal medicine

    2022  Volume 102, Page(s) 43–44

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Humans ; Janus Kinase Inhibitors/therapeutic use ; Spondylitis, Ankylosing/drug therapy ; Tumor Necrosis Factor-alpha
    Chemical Substances Antirheumatic Agents ; Janus Kinase Inhibitors ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2022-05-21
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2022.05.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Interstitial Lung Disease: How Should Therapeutics Be Implemented?

    Bruni, Cosimo / Campochiaro, Corrado / de Vries-Bouwstra, Jeska K

    Rheumatic diseases clinics of North America

    2023  Volume 49, Issue 2, Page(s) 279–293

    Abstract: Systemic sclerosis-interstitial lung disease (SSc-ILD) is a major complication of SSc resulting in important morbidity and mortality. Next to cyclophosphamide and mycophenolate mofetil, tocilizumab and nintedanib have proven efficacy in the treatment of ... ...

    Abstract Systemic sclerosis-interstitial lung disease (SSc-ILD) is a major complication of SSc resulting in important morbidity and mortality. Next to cyclophosphamide and mycophenolate mofetil, tocilizumab and nintedanib have proven efficacy in the treatment of SSc-ILD. The highly variable course of SSc-ILD, the complexity in determining and predicting the progression of SSc-ILD, and the diversity of treatment options for SSc-ILD, pose many challenges for everyday clinical practice. In this review, currently available evidence for monitoring and treatment of SSc-ILD is summarized and areas where additional evidence is highly desirable are discussed.
    MeSH term(s) Humans ; Immunosuppressive Agents/therapeutic use ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/drug therapy ; Lung Diseases, Interstitial/etiology ; Lung Diseases, Interstitial/complications ; Cyclophosphamide ; Mycophenolic Acid/therapeutic use ; Lung
    Chemical Substances Immunosuppressive Agents ; Cyclophosphamide (8N3DW7272P) ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92118-x
    ISSN 1558-3163 ; 0889-857X
    ISSN (online) 1558-3163
    ISSN 0889-857X
    DOI 10.1016/j.rdc.2023.01.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Giant cell arteritis: Update on clinical manifestations, diagnosis, and management.

    Farina, Nicola / Tomelleri, Alessandro / Campochiaro, Corrado / Dagna, Lorenzo

    European journal of internal medicine

    2022  

    Abstract: Giant cell arteritis (GCA) is the most common vasculitis affecting people older than 50 years. The last decades have shed new light on the clinical paradigm of this condition, expanding its spectrum beyond cranial vessel inflammation. GCA can be now ... ...

    Abstract Giant cell arteritis (GCA) is the most common vasculitis affecting people older than 50 years. The last decades have shed new light on the clinical paradigm of this condition, expanding its spectrum beyond cranial vessel inflammation. GCA can be now considered a multifaceted vasculitic syndrome encompassing inflammation of cranial and extra-cranial arteries and girdles, isolated or combined. Such heterogeneity often leads to diagnostic delays and increases the likelihood of acute and chronic GCA-related damage. On the other hand, the approach to suspected GCA patients has been revolutionized by the introduction of vascular ultrasound which allows a rapid, cost-effective, and non-invasive GCA diagnosis. Likewise, the use of tocilizumab is now part of the therapeutic algorithm of GCA and ensures a satisfactory disease control even in steroid-refractory patients. Nonetheless, some aspects of GCA still need to be clarified, including the clinical correlation of different histological patterns, and the prevention of long-term vascular complications. This narrative review depicts the diagnostic and therapeutic aspects of GCA most relevant in clinical practice, with a focus on clinical updates and novelties introduced over the last decade.
    Language English
    Publishing date 2022-11-04
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2022.10.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients.

    De Luca, Giacomo / Campochiaro, Corrado / Peretto, Giovanni / Busnardo, Elena / Matucci-Cerinic, Marco / Dagna, Lorenzo

    Clinical and experimental rheumatology

    2023  Volume 41, Issue 8, Page(s) 1723–1724

    MeSH term(s) Humans ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/diagnosis ; Early Diagnosis
    Language English
    Publishing date 2023-08-03
    Publishing country Italy
    Document type Letter
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/vxx4q7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Spontaneous Coronary-Artery Dissection.

    Campochiaro, Corrado / Tomelleri, Alessandro / Dagna, Lorenzo

    The New England journal of medicine

    2021  Volume 384, Issue 11, Page(s) 1077

    MeSH term(s) Arteries ; Coronary Vessel Anomalies ; Dissection ; Humans ; Vascular Diseases/diagnostic imaging
    Language English
    Publishing date 2021-03-17
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2100339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top